Patent row: Delhi HC to hear diabetes drug case
Merck had alleged that an Indian pharma company has violated its intellectual property right over its anti-diabetes medicines.
New Delhi: The patent battle between US pharmaceuticals major Merck Sharp and Dohme (MSD) and Indian firm Glenmark Pharmaceuticals over the sale of diabetes drug Januvia comes up for hearing in the Delhi High Court on Thursday. Indian pharma company Glenmark recently came out with generic versions of Merck's type-2 diabetes drugs at a 30 per cent lower price, in alleged violation of Merck's intellectual property rights.
Merck had introduced its drugs in India in 2008, pegged at one-fifth the United States price. According to market sources, a strip of seven tablets of Januvia (50 mg and 100 mg) is priced at Rs 300 while Glenmark's version costs around 30 per cent less.
MSD, in its plea, had alleged that the Indian pharma company has violated its intellectual property right (IPR) over its anti-diabetes medicines, Januvia and Janumet, by coming in the market with their own drugs containing the same salts.
(With Additional Information From PTI)
- Philippines President Duterte Does a U-turn, Says Won't Sever US Ties
- US Has Few Good Options for Response to Philippine President Duterte
- Farooq Calls Meeting of Opposition to Discuss Kashmir Issue
- Jaguar F-Pace Launch in India on October 20, Price Starts at Rs 68.4 Lakh
- DMK Will Not Let Minority Rights to be Snatched Through UCC: Stalin
- Amit Sadh Begins Shooting For Sarkar 3
- Police Targeting DMK Cadres Over Rumours About Jayalalithaa's Health: Stalin
- Boris Johnson's Anti-Brexit Article Made Public by UK Daily